Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 2:00 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1897–1920 of 13,471 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Endocrine Disorders Clear all
Active, not recruiting Phase 3 Interventional

Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy

NCT05477576
View directory record Official record
Conditions
GEP-NET, Gastroenteropancreatic Neuroendocrine Tumor, Gastroenteropancreatic Neuroendocrine Tumor Disease, Neuroendocrine Tumors, Carcinoid, Carcinoid Tumor, Pancreatic NET
Interventions
RYZ101, Everolimus, Sunitinib, Octreotide, Lanreotide
Drug
Lead sponsor
RayzeBio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
343 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
32
States / cities
Phoenix, Arizona • Duarte, California • Irvine, California + 27 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Nov 11, 2026, 2:00 PM EST
Terminated Phase 1 Interventional Results available

A Research Trial of Aralast in New Onset Diabetes (RETAIN)

NCT01183468
View directory record Official record
Conditions
Diabetes Mellitus, Type 1
Interventions
Aralast NP 45 mg dose, Aralast NP 90 mg dose, Aralast NP 180 mg dose
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
8 Years to 35 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
15
States / cities
San Diego, California • Aurora, Colorado • New Haven, Connecticut + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2018 · Synced Nov 11, 2026, 2:00 PM EST
Completed No phase listed Observational Accepts healthy volunteers

Epigenetics and the Origin of Muscle Insulin Resistance in Humans

NCT01726491
View directory record Official record
Conditions
Diabetes Mellitus Type 2 in Obese, Obesity
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
21 Years to 55 Years
Enrollment
46 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 16, 2018 · Synced Nov 11, 2026, 2:00 PM EST
Completed Phase 2 Interventional Results available

Sunitinib in Treating Patients With Metastatic Germ Cell Tumors That Have Relapsed or Not Responded to Treatment

NCT00453310
View directory record Official record
Conditions
Extragonadal Germ Cell Tumor, Ovarian Cancer, Teratoma, Testicular Germ Cell Tumor
Interventions
sunitinib malate
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years to 120 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 27, 2015 · Synced Nov 11, 2026, 2:00 PM EST
Completed Phase 1 Interventional

An Exploratory Study of the Folic Acid-tubulysin Conjugate EC1456 in Ovarian Cancer Subjects Undergoing Surgery

NCT03011320
View directory record Official record
Conditions
Ovary Cancer
Interventions
EC1456, 99mTc-Etarfolatide
Drug
Lead sponsor
Endocyte
Industry
Eligibility
18 Years and older · Female only
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Concord, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 7, 2019 · Synced Nov 11, 2026, 2:00 PM EST
Completed No phase listed Observational

Calcium Homeostasis in Acromegaly: Effect of Surgical/Medical Treatment and Comparison With Nonfunctioning Pituitary Tumors

NCT01568359
View directory record Official record
Conditions
Acromegaly, Nonfunctioning Pituitary Tumor
Interventions
Not listed
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
2
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 5, 2014 · Synced Nov 11, 2026, 2:00 PM EST
Completed No phase listed Observational

Periodontal Treatment Response in Type II Diabetic Patients

NCT01881074
View directory record Official record
Conditions
Type II Diabetes, Periodontal Disease
Interventions
Triclosan containing toothpaste, Non-triclosan containing toothpaste
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 70 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 17, 2018 · Synced Nov 11, 2026, 2:00 PM EST
Recruiting Not applicable Interventional

Stereotactic Body Radiation and Tumor Treating Fields for Locally Advanced Pancreas Cancer

NCT05679674
View directory record Official record
Conditions
Pancreas Cancer, Locally Advanced, Locally Advanced Pancreatic Adenocarcinoma
Interventions
Stereotactic Ablative Body Radiation (SABR), Tumor Treating Fields (TTF)
Radiation · Device
Lead sponsor
Baptist Health South Florida
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jan 12, 2026 · Synced Nov 11, 2026, 2:00 PM EST
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Low-Carbohydrate, Ketogenic Diet Versus Orlistat for Weight Loss

NCT00108524
View directory record Official record
Conditions
Diabetes Mellitus, Obesity
Interventions
Low carbohydrate ketogenic diet, Orlistat, Low-fat diet
Behavioral · Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years to 69 Years
Enrollment
146 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2007
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 17, 2014 · Synced Nov 11, 2026, 2:00 PM EST
Completed No phase listed Observational

Resistance to Antibiotics in Patients Receiving Eye Injections

NCT02126423
View directory record Official record
Conditions
Age-Related Macular Degeneration, Retinal Vein Occlusion, Diabetic Retinopathy
Interventions
Conjunctival and nasopharyngeal swabs
Other
Lead sponsor
Prism Vision Group
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Edison, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 1, 2016 · Synced Nov 11, 2026, 2:00 PM EST
Withdrawn Phase 1Phase 2 Interventional

Pre-operative Stereotactic Body Radiation Therapy for Pancreatic Adenocarcinoma With or Without CCX872-B

NCT03778879
View directory record Official record
Conditions
Adenocarcinoma of the Pancreas, Pancreas Cancer
Interventions
CCX872-B
Drug
Lead sponsor
Alan Katz
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jul 19, 2019 · Synced Nov 11, 2026, 2:00 PM EST
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Stevia on Satiety and Eating Attitudes in Healthy, Overweight and Obese Adults

NCT01115088
View directory record Official record
Conditions
Obesity, Type 2 Diabetes
Interventions
Aspartame, Sucrose, Stevia
Dietary Supplement
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
18 Years to 45 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2010
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Feb 12, 2016 · Synced Nov 11, 2026, 2:00 PM EST
Completed Not applicable Interventional Accepts healthy volunteers

Internet Intervention to Improve Rural Diabetes Care

NCT00403091
View directory record Official record
Conditions
Diabetes Mellitus Type 2
Interventions
Internet Intervention, Control
Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
Not listed
Enrollment
205 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2010
U.S. locations
2
States / cities
Birmingham, Alabama • Tuscaloosa, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 11, 2010 · Synced Nov 11, 2026, 2:00 PM EST
Completed Phase 3 Interventional Results available

A Maintenance Study With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer

NCT01847274
View directory record Official record
Conditions
Ovarian Neoplasms, Platinum Sensitive Ovarian Cancer
Interventions
Active comparator: Niraparib, placebo
Drug
Lead sponsor
Tesaro, Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
596 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
35
States / cities
Phoenix, Arizona • Tucson, Arizona • Los Angeles, California + 27 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2023 · Synced Nov 11, 2026, 2:00 PM EST
Not listed Not applicable Interventional

A Prospective Evaluation of Health Services Outcomes and Emerging Cardiovascular Disease Biomarkers

NCT00820313
View directory record Official record
Conditions
Coronary Heart Disease, Biomarkers of Cardiovascular Disease
Interventions
Dr. Dean Ornish Program for Reversing Heart Disease
Behavioral
Lead sponsor
Preventive Medicine Research Institute
Other
Eligibility
21 Years and older
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Sausalito, California
Source: ClinicalTrials.gov public record
Updated Jan 12, 2009 · Synced Nov 11, 2026, 2:00 PM EST
Completed Phase 4 Interventional

Grafix® DFU: Open-Label Extension Option to Evaluate Safety & Efficacy of Grafix® for Chronic Diabetic Foot Ulcers

NCT01596920
View directory record Official record
Conditions
Diabetic Foot Ulcers
Interventions
Tissue, Control
Other
Lead sponsor
Osiris Therapeutics
Industry
Eligibility
18 Years to 80 Years
Enrollment
97 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
15
States / cities
Montgomery, Alabama • Glendale, Arizona • Encinitas, California + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2014 · Synced Nov 11, 2026, 2:00 PM EST
Completed Phase 3 Interventional Results available

A Study of Tirzepatide (LY3298176) Versus Insulin Lispro (U100) in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without Metformin

NCT04537923
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Tirzepatide, Insulin Lispro (U100)
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
1,428 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
40
States / cities
Sheffield, Alabama • Fresno, California • Huntington Park, California + 36 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2023 · Synced Nov 11, 2026, 2:00 PM EST
Not yet recruiting Not applicable Interventional

A Randomized Controlled Trial of Prepared vs. Unprepared Food

NCT07800182
View directory record Official record
Conditions
Pregnant Patients at Risk of Gestational Diabetes
Interventions
Prepared meals, Unprepared Pantry/Produce box
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Nov 11, 2026, 2:00 PM EST
Active, not recruiting Phase 3 Interventional Results available

Exemestane With or Without Entinostat in Treating Patients With Recurrent Hormone Receptor-Positive Breast Cancer That is Locally Advanced or Metastatic

NCT02115282
View directory record Official record
Conditions
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Breast Adenocarcinoma, HER2/Neu Negative, Locally Advanced Breast Carcinoma, Metastatic Breast Carcinoma, Recurrent Breast Carcinoma
Interventions
Biospecimen Collection, Computed Tomography, Entinostat, Exemestane, Goserelin, Goserelin Acetate, Magnetic Resonance Imaging, Placebo Administration, Quality-of-Life Assessment
Procedure · Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
608 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2027
U.S. locations
652
States / cities
Birmingham, Alabama • Jonesboro, Arkansas • Carmichael, California + 460 more
Source: ClinicalTrials.gov public record
Updated Oct 22, 2026 · Synced Nov 11, 2026, 2:00 PM EST
Completed Not applicable Interventional

Impact of SomaSignal Tests on the Choice of Glucose-lowering Medications

NCT05166382
View directory record Official record
Conditions
Type 2 Diabetes, Cardiovascular Diseases
Interventions
Informed of results from SomaSignal Cardiovascular Risk Test in Type 2 Diabetes (CVD-T2D), Not informed of results from SomaSignal Cardiovascular Risk Test in Type 2 Diabetes (CVD-T2D)
Behavioral
Lead sponsor
University of Colorado, Denver
Other
Eligibility
40 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Mar 20, 2025 · Synced Nov 11, 2026, 2:00 PM EST
Terminated Phase 1 Interventional

Study of Gemcitabine With TheraSphere® (Yttrium-90)in Patients With Hepatic Tumors of Pancreatobiliary Origin

NCT01434459
View directory record Official record
Conditions
Pancreatic Neoplasms, Cholangiocarcinoma
Interventions
Gemcitabine with TheraSphere
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 4, 2015 · Synced Nov 11, 2026, 2:00 PM EST
Completed Not applicable Interventional

Comparison of Intraoperative Best Practice Advisory Reminders to Protocolize Insulin Administration Versus Standard Care in Patients at High Risk of Hyperglycemia

NCT05426096
View directory record Official record
Conditions
Diabetes, Hyperglycemia
Interventions
Best Practice Advisory
Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
Not listed
Enrollment
7,232 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 8, 2024 · Synced Nov 11, 2026, 2:00 PM EST
Terminated Phase 1 Interventional Results available

Study to Test the Safety and Tolerability of PF-07209960 in Advanced or Metastatic Solid Tumors

NCT04628780
View directory record Official record
Conditions
Non-small-cell Lung Cancer, Squamous Cell Carcinoma of the Head and Neck, Renal Cell Carcinoma, Urothelial Carcinoma, Colorectal Carcinoma, Ovarian Carcinoma
Interventions
PF-07209960
Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
13
States / cities
Duarte, California • Los Angeles, California • Santa Monica, California + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 29, 2024 · Synced Nov 11, 2026, 2:00 PM EST
Completed No phase listed Observational

Lancet Blood Volume Comparison Study

NCT01916096
View directory record Official record
Conditions
Diabetes
Interventions
Delica Device
Device
Lead sponsor
Facet Technologies
Other
Eligibility
18 Years to 85 Years
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Kennesaw, Georgia
Source: ClinicalTrials.gov public record
Updated Aug 5, 2013 · Synced Nov 11, 2026, 2:00 PM EST